Biomet Accepts $10.9 Bil. Private Equity Buyout To Stay Independent
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic device makers Smith & Nephew and Biomet ended discussions on a possible merger after Biomet announced plans to become a private, independent company by the end of October
You may also be interested in...
Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index
Baxter and Becton Dickinson were among large-cap hospital supply firms to prove that boring can be beautiful in 2007, as med-tech investors turned off by volatility in the sexier cardiac implant sector turned on to the relative stability of diversified, low-risk hospital products with respectable growth
Hospital Suppliers Show Vigor In ’07, With Prospects Strong For ’08 – Index
Baxter and Becton Dickinson were among large-cap hospital supply firms to prove that boring can be beautiful in 2007, as med-tech investors turned off by volatility in the sexier cardiac implant sector turned on to the relative stability of diversified, low-risk hospital products with respectable growth
Investment Advisors Argue Private Equity Offer For Biomet Is Too Low
An investor advisor group is urging Biomet shareholders to reject a proposed $10.9 billion private equity buyout because it represents too small a premium over the orthopedic company's value
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: